New Guidelines Issued on Antirheumatic Drugs for Patients Undergoing Knee or Hip Replacement — Physician’s First Watch

Medical News |
June 19, 2017

New Guidelines Issued on Antirheumatic Drugs for Patients Undergoing Knee or Hip Replacement

By Kelly Young

Edited by Susan Sadoughi, MD

The American College of Rheumatology and the American Association of Hip and Knee Surgeons have released new guidelines on managing the antirheumatic medications of patients with rheumatic diseases who are undergoing elective total knee or hip arthroplasty.

The guidelines, which are available for free in Arthritis Care & Research, include seven recommendations that are based on low-to-moderate quality of evidence. Among them:

  • Patients can continue taking non-biologic disease-modifying antirheumatic drugs (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) during the perioperative period.

  • Biologic medications (e.g., adalimumab, etanercept) should be withheld for about one dosing schedule before elective surgery. They can be resumed once there is evidence of wound healing — a minimum of 14 days.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.